pipelin newsflow set
mani pipelin opportun next year repres
singl doubl ahead big readout ibranc
earli breast cancer bump pt
continu rate share ow base upon improv
pipelin prospect acceler growth earli next decad
bump pt increas pt ep
unchang estimate bull case center
acceler growth earli next decad pleas refer report
watch pipelin list potenti blockbust exhibit
new indic exist drug other yet-to-b defin
drug cancer describ seven key pipelin event text
also list four oncolog candid fda action late exhibit
plu three import long-term pipelin readout exhibit ibranc earli
adjuv breast cancer biggest driver theoret opportun
ph result expect late
current project pipelin sale half new candid
half ibranc adjuv new drug launch estim total
global sale ibranc adjuv sale amount
note ibranc adjuv sale bake ibranc sale line
annual revenu model start start base ibranc sale
assum adjuv ad label estimate sale
rise
tafamadi attr-act trial present esc mon aug
germani munich hold webcast
aug march announc tafamidi significantli
reduc all-caus death cardiovascular-rel hospit vs placebo
transthyretin cardiomyopathi month await detail data see
magnitud benefit transthyretin cardiomyopathi potenti could
signific opportun patient accord
estim diagnosi challeng diagnos per
major pharmaceut unit state america
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
estim physician awar diseas mani disord
much common caus cardiomyopathi biopsi typic
requir diagnosi result current project
global sale could upsid project mortal benefit
highli compel abl drive higher diagnosi
ibranc pallet readout come month potenti lead indic
adjuv surgeri breast cancer result sale potenti
pallet small investigator-l trial compar ibranc letrozol vs
letrozol neoadjuv surgeri breast cancer primari endpoint
chang prolifer biomark clinic complet respons
ccr week pallet fileabl trial result could drive
percept ph readout ibranc phase adjuv
surgeri outcom trial palla penelope-b
set report late howev read-through pallet
palla penelope-b would fairli limit either direct due
surgeri vs post-surgeri use surrog endpoint
jak tyk question pfizer decid compound
move phase alopecia phase trial evalu pf-
inhibitor monotherapi inhibitor
monotherapi vs placebo primari efficaci endpoint chang baselin
sever alopecia tool score week complet primari
final expect august
tanezumab pain long-term safeti data expect run
week placebo/act comparator-control safeti studi hip/kne
osteoarthr oa chronic lower back pain clbp
patient receiv tanzeumab everi eight week seven inject
safeti follow-up final complet feb jan
respect oa trial test mg mg clbp trial test
mg mg key safeti data also hip/kne
oa trial tanezumab mg vs placebo safeti
followup final complet nov cancer pain trial
tanzeumab mg vs placebo opioid background
safeti follow-up final complet jul would book end-us
sale share gross profit develop expens certain
commerci expens equal lilli
phase atop dermat readout expect jade mono-
jade compar inhibitor
vs placebo primari endpoint investig global assess
eczema area sever index easi week
readout expect clover enrol patient risk
develop diff infect cdi primari efficaci endpoint cdi
expect domagrozumab antibodi target myostatin
phase trial three domagrozumab week
domagrozumab week follow placebo week placebo
week follow domagrozumab week primari efficaci
endpoint mean chang baselin four-stair climb week
exhibit potenti blockbust opportun xtandi xeljanz
recent approv respect indic
exhibit fda action date four target cancer agentsal grant
prioriti review fda
exhibit three key pipelin product besid ibranc adjuv ph
 next-gen prevnar
readout
readout coupl year away
overweight pfizer share given
revenu earn growth
acceler start late patent
base case ep compar peer group average
believ averag near-term growth compound-annual-growth-rate
revenu ep off-set acceler growth
compound-annual-growth-rate revenu ep patent expir
fade pipelin kick
ep
ep
oncolog franchis financi upsid drive ep forecast strateg
action enhanc growth prospect cancer drug financi leverag drive
combin ep upsid stock multipl expand conjunct
posit pipelin newsflow strateg activ enhanc growth prospect
ep
ep
deliv financi perform line expect multipl
expand acceler growth earli next decad approach ibranc ex-u
sale ramp strongli pipelin progress encourag
financi result rel expect
ibranc growth driver perform
risk achiev price
upsid risk core busi upsid
transact boost sharehold valu
ep
ep
financi pipelin disappoint plu competit threat rise revenu fall
short due competit pressur ep miss price-to-earnings contract
due financi pipelin disappoint plu grow competit threat
downsid risk financi shortfal
price develop overpay
futur legal disappoint
exhibit probabl adjust pipelin
tanezumab ngf pain pay gp
exhibit probabl adjust pipelin
pipelin sale
